Skip to main content
Premium Trial:

Request an Annual Quote

Helicos Expands Licensing Deal with Arizona Technology Enterprise

NEW YORK (GenomeWeb News) – Helicos BioSciences has amended a licensing deal with Arizona Technology Enterprise to include the rights to sequencing-based detection methods that do not rely on optically-labeled nucleotides, the Cambridge, Mass.-based firm announced after the close of the market on Tuesday.

The amended agreement now gives Helicos patent rights to several sequencing-by synthesis methods and includes "all activities that fall within the scope of, or constitute the practice of, the licensed patents, and give Helicos full and unencumbered rights to the associated intellectual property," it said.

In 2005 Helicos exclusively licensed certain patent rights and patent applications from ATE, which had previously licensed them from Arizona State University and the University of Alberta.

Under the amended agreement, Helicos remains obligated to pay ATE an undisclosed percentage of income from Helicos-granted sub-licenses or other transfers of the ATE licensed rights, including any sale of the company or settlement of litigation, Helicos said in a document filed with the US Securities and Exchange Commission on Tuesday.

Additional financial terms of the amended licensing deal were not disclosed.

Ivan Trifunovich, president and CEO of Helicos, said in a statement that the "newly acquired rights will be an important asset in our licensing and IP monetization efforts" that also include a lawsuit it has filed against Illumina, Life Technologies, and Pacific Biosciences alleging patent infringement of its single-molecule sequencing technology.

Earlier this month Helicos reported a 22 percent increase in its second-quarter revenues.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.